Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14-9957-80 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- HLA-G Monoclonal Antibody (87G), eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The monoclonal antibody 87G recognizes human HLA-G, a member of the Human Leukocyte Antigen family but as part of the nonclassical MHC type involved in inhibiting immune reponses. HLA-G has seven reported isoforms. The antibody 87G recognizes both HLA-G1 and the solube HLA-G5. Expression of HLA-G is found primarily in fetal trophoblast cells as they invade the maternal decidua thereby protecting the fetus from the maternal immune system. Like the highly mitotic trophoblast, abundant HLA-G protein expression has been identified in some tumors, including melanoma, breast carcinoma and renal carcinoma as well as CLL, AML and B-CLL. Some expression has also been found in pancreatic islets, erythroid and endothelial progenitors and the adult thymic medulla.HLA-G+ CD4 or CD8 cells have been identified in normal human peripheral blood and are thought to act as regulatory cells in that they are hypoproliferative with a unique cytokine profile differing from Tregs. The receptors for HLA-G are CD85j/ILT2, CD85d/ILT4, and CD158. Recent studies have shown a role for HLA-G in tolerance and maintenance of transplanted organs.
- Antibody clone number
- 87G
- Concentration
- 0.5 mg/mL
Submitted references Placental endovascular extravillous trophoblasts (enEVTs) educate maternal T-cell differentiation along the maternal-placental circulation.
The Killer Cell Ig-like Receptor 2DL4 Expression in Human Mast Cells and Its Potential Role in Breast Cancer Invasion.
L3MBTL1 deficiency directs the differentiation of human embryonic stem cells toward trophectoderm.
Beyond the increasing complexity of the immunomodulatory HLA-G molecule.
Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition.
Ma Y, Yang Q, Fan M, Zhang L, Gu Y, Jia W, Li Z, Wang F, Li YX, Wang J, Li R, Shao X, Wang YL
Cell proliferation 2020 May;53(5):e12802
Cell proliferation 2020 May;53(5):e12802
The Killer Cell Ig-like Receptor 2DL4 Expression in Human Mast Cells and Its Potential Role in Breast Cancer Invasion.
Ueshima C, Kataoka TR, Hirata M, Furuhata A, Suzuki E, Toi M, Tsuruyama T, Okayama Y, Haga H
Cancer immunology research 2015 Aug;3(8):871-80
Cancer immunology research 2015 Aug;3(8):871-80
L3MBTL1 deficiency directs the differentiation of human embryonic stem cells toward trophectoderm.
Hoya-Arias R, Tomishima M, Perna F, Voza F, Nimer SD
Stem cells and development 2011 Nov;20(11):1889-900
Stem cells and development 2011 Nov;20(11):1889-900
Beyond the increasing complexity of the immunomodulatory HLA-G molecule.
Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J
Blood 2008 May 15;111(10):4862-70
Blood 2008 May 15;111(10):4862-70
Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition.
Ishitani A, Sageshima N, Lee N, Dorofeeva N, Hatake K, Marquardt H, Geraghty DE
Journal of immunology (Baltimore, Md. : 1950) 2003 Aug 1;171(3):1376-84
Journal of immunology (Baltimore, Md. : 1950) 2003 Aug 1;171(3):1376-84
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of stimulated U937 cells with 0.25 µg of Mouse IgG2a K Isotype Control Purified (Product # 14-4724-82) (blue) or 0.25 µg of Anti-Human HLA-G Purified (purple) followed by F (ab')2 Anti-Mouse IgG PE (Product # 12-4012).Total viable cells were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- FIGURE 2 Identification of TGF-beta1-producing cells at the maternal-foetal interface in normal pregnancy at gestational weeks 7-9. A-C, In situ hybridization of TGF-beta1 (blue) and immunohistochemistry staining of HLA-G (yellow in A and B) or CD31 (yellow in C) in normal pregnant decidua. Middle panels are enlargement of the rectangular areas in left panels, showing the enEVTs in remodelled SPA (A), iEVTs in the area nearby the remodelled SPA (B) and dECs in unremodelled SPA (C). Right panels are negative control of in situ hybridization, with the immunohistochemistry signals of HLA-G (A, B) or CD31 (C). D, E, Immunofluorescence of HLA-G (red) and NCAM1 (green) in remodelled SPA (D) and the area nearby remodelled SPA (E). F, Flow cytometry of TGF-beta1 expression in EVTs of normal pregnancy. Left panel, FACS isolation of enEVTs and iEVTs with antibodies against HLA-G and NCAM1. Middle panel, flow cytometry of TGF-beta1-positive enEVTs that are gated from the left panel as HLA-G + NCAM1 + . Right panel: flow cytometry analysis of TGF-beta1-positive iEVTs that were gated from the left panel as HLA-G + NCAM1 - . G, FACS isolation of CD31 + NCAM1 - dECs in normal pregnancy (left panel), and flow cytometry of TGF-beta1-positive dECs gated from the left panel as CD31 + NCAM1 - (right panel). H, The statistical analysis of TGF-beta1-positive primary cells based on the results from 5 normal pregnant cases. I, ELISA for TGF-beta1 in supernatants of the FACS-sorted enEVTs, iEVTs and
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- FIGURE 3 The number of enEVTs and TGF-beta1-producing enEVTs in RSA pregnancy. A, Flow cytometry of enEVTs with antibodies against HLA-G and NCAM1 in RSA pregnancy (left panel). Flow cytometry of TGF-beta1-positive enEVTs that are gated from the left panel as HLA-G + NCAM1 + in RSA pregnancy (right panel). B, The statistical analysis of the number of enEVTs in normal (n = 5) and RSA (n = 5) pregnancy. C, The statistical analysis of the proportion of TGF-beta1-producing enEVTs in normal (n = 5) and RSA (n = 5) pregnancy. D, ELISA for TGF-beta1 in supernatants of the normal enEVTs (n = 3) and RSA enEVTs (n = 3). Data are presented as mean +- SD, and comparison between groups was performed with Student's t test. *, P < .05